Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2AG4O
|
|||
| Drug Name |
DNL593
|
|||
| Synonyms |
TAK-594
Click to Show/Hide
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Frontotemporal dementia [ICD-11: 6D83] | Phase 1/2 | [1] | |
| Company |
TAKEDA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Progranulin (PGRN) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05262023) A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Denali | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.